Rhumbline Advisers cut its position in shares of Qiagen (NYSE:QGEN - Free Report) by 5.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 194,303 shares of the company's stock after selling 11,088 shares during the quarter. Rhumbline Advisers owned about 0.09% of Qiagen worth $7,801,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in QGEN. Groupama Asset Managment boosted its holdings in Qiagen by 8,074.0% in the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after acquiring an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Qiagen by 9.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after acquiring an additional 2,202,040 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Qiagen by 2.5% in the fourth quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock worth $970,534,000 after acquiring an additional 531,362 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Qiagen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after acquiring an additional 77,119 shares in the last quarter. Finally, Norges Bank bought a new stake in Qiagen in the fourth quarter worth $181,529,000. 70.00% of the stock is currently owned by institutional investors.
Qiagen Stock Performance
Qiagen stock traded down $0.31 during mid-day trading on Friday, reaching $47.08. 1,064,958 shares of the stock traded hands, compared to its average volume of 1,187,222. The stock has a market capitalization of $10.46 billion, a PE ratio of 131.08, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. Qiagen has a 12-month low of $37.63 and a 12-month high of $49.30. The business's 50-day moving average is $42.98 and its 200-day moving average is $42.22.
Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Qiagen's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 earnings per share. As a group, sell-side analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the company. Robert W. Baird boosted their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Finally, Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $48.42.
Read Our Latest Stock Analysis on Qiagen
About Qiagen
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
